US00534A1025 - Common Stock
Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in...
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
After hours stock analysis on 2024-03-22: top gainers and losers in today's session.
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced interim exploratory COVID-19 clinical event data for VYD222, an investigational, monoclonal antibody (mAb) in development for the pre-exposure prophylaxis of COVID-19. The data announced today from the ongoing Phase 3 CANOPY clinical trial reflect and add further to the initial potential signal of clinical protection from symptomatic COVID-19 shared in December 2023, and may be useful in updating prior published work that analyzed the relationships between serum virus neutralizing antibody (sVNA) titers and protection in patients who had no prior exposure to vaccination or natural infection.1
PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency...
Invivyd (IVVD) stock was down 13% in late morning trading Monday in the wake of news that the company had concerns about its ability to stay in business long term. Read more here.
Invivyd files prospectus for resale of 37.75M common shares by selling stockholders; SEC filing linked.
WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from...
These are several biotech companies for investors seeking unique opportunities for great returns within the industry.
The biggest pre-market stock movers for Wednesday are ready to go as we break down all of the latest news moving shares today!
Invivyd (IVVD) has requested FDA Emergency Use Authorization for its treatment VYD222 for the prevention of COVID-19 in immunocompromised people. Read more here.
The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.
Invivyd (IVVD) shares retreated 16% Tuesday after soaring 120% in the prior session on positive Phase 3 data for its COVID-19 drug VYD222. Read more here.
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19...
Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19Company expects to have...